NEW YORK (GenomeWeb News) — Whatman today said it will provide DNA collection kits based on its FTA elute technology to an international prostate cancer pharmacogenotyping study that aims to uncover links between SNPs and drug efficacy, side-effects, or individual susceptibility to prostate cancer.
The study is part of the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy trial, also known as STAMPEDE.
STAMPEDE is a multi-stage randomized controlled trial for around 3,300 patients with newly diagnosed advanced prostate cancer or for patients with a rapid PSA rise following previous surgery or radiotherapy.
The sub study is designed to study the metabolic pathways by which androgen blocking drugs affect patients, and to examine how genes affect drugs by comparing the response to one of six treatment combinations.
Each of the patients will have the option to contribute a sample of genetic material using the Whatman FTA Elute kit, which uses a chemically treated matrix that lyses cells and immobilizes nucleic acids on contact, enabling scientists to collect, transport, archive, and isolate DNA and RNA samples at room temperature in a single step.
Next, the sub study will isolate small sections of the DNA to identify SNP biomarkers that differentiate how patients may respond to a given therapy. “Researchers hope to uncover links between certain SNPs and drug efficacy, side-effects, or individual susceptibility to prostate cancer,” Whatman said in a statement.
The study is being conducted through the UK Medical Research Council Clinical Trials Unit in London and the University of Birmingham. It is sponsored by the British Medical Research Council, funded by Cancer Research UK, and supported by the National Cancer Research Institute and National Cancer Research Network.